Log in to save to my catalogue

The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results...

The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1811894541

The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium

About this item

Full title

The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium

Publisher

United States: Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins

Journal title

The American journal of gastroenterology, 2016-08, Vol.111 (8), p.1147-1155

Language

English

Formats

Publication information

Publisher

United States: Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins

More information

Scope and Contents

Contents

We assessed the real-world effectiveness and safety of vedolizumab (VDZ) in moderate-severe Crohn's disease (CD).
Retrospective cohort study of seven medical centers, from May 2014 to December 2015. Adults with moderate-severe CD treated with VDZ, with follow-up after initiation of therapy, were included. Using the multivariable Cox proportional...

Alternative Titles

Full title

The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1811894541

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1811894541

Other Identifiers

ISSN

0002-9270

E-ISSN

1572-0241

DOI

10.1038/ajg.2016.236

How to access this item